Monopar Therapeutics Inc.
MNPR
$59.27
-$1.72-2.82%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -13.72M | -19.44M | -17.31M | -16.57M | -15.59M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.12M | 8.56M | 7.66M | 6.71M | 5.68M |
| Change in Net Operating Assets | -2.61M | 56.40K | -159.80K | -552.30K | 3.50M |
| Cash from Operations | -12.20M | -10.83M | -9.81M | -10.41M | -6.40M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -63.45M | -15.60M | -12.49M | -13.68M | -14.34M |
| Cash from Investing | -63.45M | -15.60M | -12.49M | -13.68M | -14.34M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 127.79M | 184.00M | 56.22M | 56.22M | 59.40M |
| Repurchase of Common Stock | -36.22M | -35.90M | -536.10K | -224.50K | -104.10K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 91.57M | 148.10M | 55.69M | 55.99M | 59.29M |
| Foreign Exchange rate Adjustments | 97.20K | -6.10K | -2.00K | 2.10K | 500.00 |
| Miscellaneous Cash Flow Adjustments | 0.00 | 0.00 | -- | -- | -- |
| Net Change in Cash | 16.02M | 121.66M | 33.38M | 31.90M | 38.55M |